27 June 2017
Cataracts and Glaucoma – all you need to know.
Some of the principal treatments carried out by Dr David Farrugia at Spire include:Back to top
Dr David Farrugia MD FRCP PhD was appointed in September 2000 as the first Consultant Medical Oncologist in Gloucestershire and what was then the 3 Counties Cancer Network. He qualified from the University of Malta Medical school in 1987 and underwent general medical training in London. He trained in Medical Oncology at Guy’s and St Thomas’ Hospitals, St. Bart’s Hospital and The Royal Marsden Hospital in London. He read a Doctoral Thesis (PhD) on the Clinical Pharmacology of new Antifolate Cancer Drugs at the Institute of Cancer Research, Royal Marsden Hospital and University of London in 1998.
His areas of specialisation include colorectal (bowel) and lung cancer, kidney cancer, melanoma, neuroendocrine (carcinoid) tumours and cancer of unknown primary (CUP). He is the local Principal Investigator in a number of clinical trials, both national and international, looking at new therapies and the role of genetics in the personalised treatment of cancer. He is a member of the American Society of Clinical Oncology and the European Society of Medical Oncology, as well as specialist UK organisations for the treatment of melanoma, lung cancer and Neuroendocrine tumours. He has several publications in peer-reviewed journals and has received a merit award from the American Society of Clinical Oncology.
|Private secretary telephone||0300 4222392|
Consultant Medical Oncologist, Gloucestershire Hospitals NHS Foundation Trust.Back to top
Holds less than 0.1% of the shares in Spire Healthcare Group plc.Back to top
07 June 2017
Deciding to have weight loss surgery is a decision that requires careful consideration and support.